MapLight Therapeutics, Inc. (MPLT)
NASDAQ: MPLT · Real-Time Price · USD
37.44
+1.45 (4.03%)
Jul 21, 2026, 4:00 PM EDT - Market closed
MapLight Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, MapLight Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $43.23. The average 1-year stock price forecast is 15.46% higher than the current stock price, while the lowest is $34 (-9.19%) and the highest is $60 (+60.26%).
Price Target: $43.23 (+15.46%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for MapLight Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 9 | 10 | 12 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 7 | 11 | 12 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Initiates $38 → $46 | Buy | Initiates | $38 → $46 | +22.86% | Jul 20, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $45 | Buy | Reiterates | $45 | +20.19% | Jul 14, 2026 |
| Needham | Needham | Buy Reiterates $40 → $45 | Buy | Reiterates | $40 → $45 | +20.19% | Jul 10, 2026 |
| Raymond James | Raymond James | Buy Initiates $46 | Buy | Initiates | $46 | +22.86% | Jun 24, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $43 → $40 | Buy | Maintains | $43 → $40 | +6.84% | Jun 23, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
20.00M
EPS This Year
-5.14
from -18.56
EPS Next Year
-3.74
from -5.14
EPS and Forward PE are based on non-GAAP adjusted numbers.